2013
DOI: 10.1016/j.bbamcr.2013.04.012
|View full text |Cite
|
Sign up to set email alerts
|

p27 suppresses cyclooxygenase-2 expression by inhibiting p38β and p38δ-mediated CREB phosphorylation upon arsenite exposure

Abstract: p27 is a cyclin-dependent kinase (CDK) inhibitor that suppresses a cell’s transition from G0 to S phase, therefore acting as a tumor suppressor. Our most recent studies demonstrate that upon arsenite exposure, p27 suppresses Hsp27 and Hsp70 expressions through the JNK2/c-Jun- and HSF-1-dependent pathways, suggesting a novel molecular mechanism underlying the tumor suppressive function of p27 in a CDK-independent manner. We found that p27-deficiency (p27−/−) resulted in the elevation of cyclooxygenase-2 (COX-2)… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
8
0

Year Published

2014
2014
2019
2019

Publication Types

Select...
9

Relationship

5
4

Authors

Journals

citations
Cited by 13 publications
(10 citation statements)
references
References 65 publications
2
8
0
Order By: Relevance
“…Mutating the putative CRE sequences, but not SBE sites, severely reduced Stat3 promoter activity in p27 2/2 MEFs, indicating that p27 inhibited Stat3 transcription by abrogating CRE activity. Our results presented here are consistent with our recent finding that p27 suppresses Cox-2 transcription in a CREdependent manner during arsenite exposure (Che et al, 2013).…”
Section: /2supporting
confidence: 83%
“…Mutating the putative CRE sequences, but not SBE sites, severely reduced Stat3 promoter activity in p27 2/2 MEFs, indicating that p27 inhibited Stat3 transcription by abrogating CRE activity. Our results presented here are consistent with our recent finding that p27 suppresses Cox-2 transcription in a CREdependent manner during arsenite exposure (Che et al, 2013).…”
Section: /2supporting
confidence: 83%
“…Our most recent studies demonstrated that acute exposure to 20μM arsenite shows comparable responses with chronic exposure to 1μM arsenite for two months [25]. Thus, arsenite dose of 20 μM was selected for current short term exposure.…”
Section: Resultsmentioning
confidence: 99%
“…As described in our previous studies (27, 32), dual-luciferase reporter assay was performed with the luciferase assay system (Promega Corp., Madison, WI). Each of the indicated luciferase reporter was transfected into human bladder cancer cells.…”
Section: Methodsmentioning
confidence: 99%